Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs

BACKGROUND: Geographic variation in the use of prescription drugs, particularly those deemed harmful by the FDA, may lead to variation in patient exposure to adverse drug events. One such drug is the glucose-lowering drug rosiglitazone, for which the FDA issued a safety alert on May 21, 2007, follow...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahuja, Vishal, Sohn, Min-Woong, Birge, John R., Syverson, Chad, Budiman-Mak, Elly, Emanuele, Nicholas, Cooper, Jennifer M., Huang, Elbert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861222/
https://www.ncbi.nlm.nih.gov/pubmed/26679970
http://dx.doi.org/10.18553/jmcp.2015.21.12.1214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861222/
https://www.ncbi.nlm.nih.gov/pubmed/26679970
http://dx.doi.org/10.18553/jmcp.2015.21.12.1214

Ejemplares similares